Cargando…
Salt‐Inducible Kinase 2‐Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis
Salt‐inducible kinase 2 (SIK2) is a promising target for ovarian cancer therapy due to its critical role in tumorigenesis and progression. Currently available SIK2 inhibitors have shown remarkable therapeutic effects on ovarian cancers in preclinical studies. However, direct administration of the SI...
Autores principales: | Hua, Yue, Yin, Han, Liu, Xiaoyang, Xie, Jinbing, Zhan, Wenjun, Liang, Gaolin, Shen, Yang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353504/ https://www.ncbi.nlm.nih.gov/pubmed/35618488 http://dx.doi.org/10.1002/advs.202202260 |
Ejemplares similares
-
Weak acid-initiated slow release of Dexamethasone from hydrogel to treat orbital inflammation
por: Li, Jinjing, et al.
Publicado: (2023) -
Assembly drives regioselective azide-alkyne cycloaddition reaction
por: Jiang, Qiaochu, et al.
Publicado: (2023) -
Tension can directly suppress Aurora B kinase-triggered release of kinetochore-microtubule attachments
por: de Regt, Anna K., et al.
Publicado: (2022) -
Ultrasound-triggered nicotine release from nicotine-loaded cellulose hydrogel
por: Iresha, Harshani, et al.
Publicado: (2021) -
Optimization of Tyrosine Kinase Inhibitor-Loaded Gold Nanoparticles for Stimuli-Triggered Antileukemic Drug Release
por: Tatar, Andra-Sorina, et al.
Publicado: (2023)